Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRIT20250224008
- Term of Validity
- 24 February 2025 - 24 February 2026
- Company's Country
- Italy
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The italian company is an innovative startup specializing in AI-driven metabolic analysis. Their DMA® technology enables non-invasive, AI-powered screening for early diagnosis and personalized treatment. By detecting metabolic patterns, it enhances preventive care, chronic disease management and sports performance. They seek AI, data integration and sensor technology partners to integrate their cutting-edge solution into healthcare, improving diagnostics and patient outcomes.
- Full Description
-
The italian company is an innovative startup specializing in AI-driven metabolic analysis of human physiology and pathology. Their proprietary Deep Metabolism Assessment (DMA®) technology is revolutionizing healthcare through a non-invasive, highly accurate method for early diagnosis and personalized treatment. At the core of this innovation lies DMA®, which leverages bioelectrical activity to uncover metabolic patterns linked to physiological and pathological conditions. This advanced system detects and analyzes spontaneous electrical currents emitted by the human body, offering valuable insights into metabolic states. Using ultra-sensitive sensors capable of measuring nanoAmpere-range electrical signals, the start-up has mapped 61 key reference points across the body, covering 30 brain regions and multiple organs to assess metabolic processes affecting health. The assessment involves measuring baseline electrical activity at these reference points and observing variations after indirect exposure to specific biomarkers—biomolecules essential to physiological balance. This enables to identify metabolic deficiencies, increased metabolic demands and pathological processes. DMA® can detect imbalances in amino acids and trace elements, recognize metabolic stress markers like Myc and Ras proteins in tumors and assess neurodegenerative conditions by analyzing phosphorylated Tau in Alzheimer's disease. It can also identify bacterial, viral and parasitic infections based on their bioelectrical signatures. Company database includes over 1,500 biomarkers, continuously updated with new scientific discoveries. One of DMA®'s greatest advantages is its non-invasive nature. Unlike traditional methods requiring blood samples, biopsies or imaging, DMA® enables painless, real-time metabolic monitoring. This facilitates continuous health assessments, making it ideal for early disease detection, preventive care and personalized medicine. By identifying metabolic deviations before symptoms manifest, healthcare providers can intervene proactively, improving patient outcomes. For chronic disease management, DMA® offers unparalleled advantages. Continuous metabolic tracking allows physicians to tailor treatments in real-time, optimizing therapeutic efficacy. This is particularly valuable for conditions like diabetes, cardiovascular diseases and autoimmune disorders, where dynamic treatment adjustments improve health outcomes. Beyond clinical applications, DMA® is transforming sports medicine and performance optimization. Athletes benefit from precise metabolic insights that inform training, recovery and injury prevention. Understanding their metabolic responses enables data-driven adjustments to enhance performance and longevity. The AI-powered analytical algorithms enhance DMA® assessments' accuracy and reliability, minimizing false positives and negatives. This breakthrough in bioelectrical analysis represents a paradigm shift in diagnostics, opening new frontiers in medical research and clinical practice. The implications extend beyond patient care—by streamlining diagnostics and improving accuracy. DMA® reduces healthcare costs, optimizes resource allocation and enhances medical efficiency.
As demand for preventive and personalized healthcare grows, this technology stands at the forefront, redefining diagnostics, treatment and long-term health management.
Having secured competitive funding (Smart&Start, PREVEDO) and key collaborations (CNR MISTER, University of Salerno), the start-up seeks partners in order to:
● Enhancing analytical models with a hybrid approach combining explicit and implicit ML models
● Integrating DMA® datasets with imaging, ECG, EEG and biometric data from wearable devices
● Improving the sensor technology for greater precision and expanded diagnostic capabilities - Advantages and Innovations
-
Revolutionary Non-Invasive Technology – DMA® provides a painless, real-time metabolic assessment, eliminating the need for invasive procedures such as biopsies or blood tests.
● Early Disease Detection – By identifying metabolic imbalances before symptoms appear, DMA® enables proactive interventions, improving patient outcomes and advancing preventive medicine.
● Comprehensive and Multi-System Analysis – The technology can evaluate metabolic activity across 30 brain regions and multiple organs, offering an unprecedented level of diagnostic depth.
● AI-Powered Precision – Advanced machine learning algorithms enhance diagnostic accuracy, ensuring precise identification of metabolic markers while minimizing false positives and negatives.
● Expansive Biomarker Library – With over 1,500 biomarkers and continuous updates based on scientific discoveries, DMA® provides a robust framework for assessing a wide spectrum of health conditions.
● Personalized Treatment Optimization – By monitoring real-time metabolic responses, DMA® enables tailored therapeutic strategies, optimizing treatments for chronic diseases like diabetes, cardiovascular disorders and autoimmune conditions.
● Enhanced Sports Performance & Recovery – Athletes benefit from detailed metabolic insights that inform training, recovery and injury prevention, maximizing performance longevity.
● Rapid and Cost-Effective Assessments – The efficiency of DMA® reduces diagnostic timelines and healthcare costs, improving accessibility and resource allocation in clinical settings.
● Scalable and Future-Ready – The flexibility of the platform ensures seamless integration with evolving healthcare technologies, solidifying DMA® as a cornerstone of the future of precision medicine. - Technical Specification or Expertise Sought
-
The italian start-up is seeking partners to collaborate on advancing research and development under the Eureka framework. Their objectives focus on enhancing the analytical capabilities and expanding the applications of their technology through interdisciplinary innovation.
Specifically, they aim to:
● Enhance analytical models by developing a hybrid approach that integrates explicit and implicit machine learning (ML) models, improving predictive accuracy and data interpretation
● Integrate DMA® technology datasets with complementary data sources, including imaging, ECG, EEG and biometric data from wearable devices, to create a more comprehensive diagnostic framework
● Optimize sensor performance by improving sensitivity, accuracy and adaptability to various research and clinical applications. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 9: Industry, Innovation and Infrastructure
- Goal 10: Reduced Inequality
Partner Sought
- Expected Role of a Partner
-
The start-up is looking for partners who can actively contribute to the enhancement and validation of DMA® technology.
The expected roles of the partners include:
● Development of advanced analytical models: Collaborators will support the refinement and validation of hybrid ML models to improve predictive accuracy and ensure reliable metabolic analysis outcomes.
● Data integration and multi-source analysis: They seek partners who can contribute to merging DMA® data with complementary datasets (e.g., imaging, ECG, EEG and biometric data from wearables), enhancing the diagnostic framework.
● Sensor optimization and technology improvement: Partners with expertise in sensor design, wearable devices and bioelectrical measurement will collaborate to refine DMA® sensors, improving their accuracy and adaptability for both clinical and research applications. - Type and Size of Partner
- SME 11-49
- SME 50 - 249
- SME <=10
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Eureka
- Call title and identifier
-
Eurostars call for projects MAR 2025
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Web link to the call
- https://eurekanetwork.org/opencalls/eurostars-call-for-projects-mar-2025/
- Eureka
Dissemination
- Technology keywords
- 01003003 - Artificial Intelligence (AI)
- 01004001 - Applications for Health
- 09003 - Electronic measurement systems
- 06005003 - Health information management
- 06005002 - Sensors & Wireless products
- Market keywords
- 05007004 - Monitoring equipment
- 05004001 - Electromedical and medical equipment
- 05001001 - Diagnostic services
- 05003001 - Therapeutic services
- 05004005 - Diagnostic equipment
- Targeted countries
- All countries
